本研究工作为CD19-L的生物工程版本（一种重组的人类生物治疗因子，其靶标为CD19阳性白血病干细胞）的首篇报告。
This work represents the first report of a bioengineered version of CD19-L, a recombinant human biotherapeutic agent, targeting CD19-positive leukemic stem cells.
该重组蛋白不仅显示了与白血病细胞的选择性整合特征，同时可使白血病细胞在24小时内即被迅速摧毁。
This recombinant protein not only shows selective binding to leukemia cells but also causes their rapid destruction within 24 hours.
该重组蛋白不仅显示了与白血病细胞的选择性整合特征，同时可使白血病细胞在24小时内即被迅速摧毁。
This recombinant protein not only shows selective binding to leukemia cells but also causes their rapid destruction within 24 hours.
应用推荐